Eton Pharmaceuticals to Participate in Upcoming Investor Conferences
DEER PARK, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that executive management will participate in three upcoming investor conferences as follows:
-
The 26th Annual B. Riley Securities Investor Conference
Date: Wednesday, May 20, 2026
Location: The Ritz-Carlton, Marina Del Rey, California
-
The 23rd Annual Craig-Hallum Institutional Investor Conference
Date: Thursday, May 28, 2026
Location: Depot Renaissance Hotel Minneapolis, Minnesota
-
Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026 at 9:55-10:25AM ET
Location: New York, New York
Webcast: Click Here
There are no presentations for the B. Riley Securities and Craig-Hallum conferences.
About Eton Pharmaceuticals
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has ten commercial rare disease products: KHINDIVI™, INCRELEX®, ALKINDI SPRINKLE®, DESMODA™, GALZIN®, HEMANGEOL®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.
Investor Relations:
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
